David Rescott
Stock Analyst at Truist Securities
(3.87)
# 663
Out of 5,114 analysts
77
Total ratings
63.93%
Success rate
7.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Rescott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Buy | $21 → $23 | $20.38 | +12.86% | 8 | Dec 18, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $88 → $87 | $85.66 | +1.56% | 7 | Dec 16, 2025 | |
| HAE Haemonetics | Maintains: Outperform | $87 → $99 | $80.21 | +23.43% | 2 | Dec 15, 2025 | |
| MDT Medtronic | Maintains: Neutral | $103 → $109 | $98.63 | +10.51% | 8 | Nov 19, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $63 → $70 | $62.82 | +11.43% | 6 | Nov 13, 2025 | |
| BSX Boston Scientific | Maintains: Outperform | $123 → $128 | $95.61 | +33.88% | 9 | Oct 1, 2025 | |
| PEN Penumbra | Maintains: Buy | $300 → $310 | $315.90 | -1.87% | 31 | Jul 30, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $111 → $110 | $87.70 | +25.43% | 3 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $600 → $575 | $572.47 | +0.44% | 3 | Apr 23, 2025 |
SI-BONE
Dec 18, 2025
Maintains: Buy
Price Target: $21 → $23
Current: $20.38
Upside: +12.86%
Edwards Lifesciences
Dec 16, 2025
Maintains: Neutral
Price Target: $88 → $87
Current: $85.66
Upside: +1.56%
Haemonetics
Dec 15, 2025
Maintains: Outperform
Price Target: $87 → $99
Current: $80.21
Upside: +23.43%
Medtronic
Nov 19, 2025
Maintains: Neutral
Price Target: $103 → $109
Current: $98.63
Upside: +10.51%
LivaNova
Nov 13, 2025
Maintains: Outperform
Price Target: $63 → $70
Current: $62.82
Upside: +11.43%
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $123 → $128
Current: $95.61
Upside: +33.88%
Penumbra
Jul 30, 2025
Maintains: Buy
Price Target: $300 → $310
Current: $315.90
Upside: -1.87%
Merit Medical Systems
Apr 25, 2025
Maintains: Outperform
Price Target: $111 → $110
Current: $87.70
Upside: +25.43%
Intuitive Surgical
Apr 23, 2025
Maintains: Outperform
Price Target: $600 → $575
Current: $572.47
Upside: +0.44%